NUVB · Stock research · Public disclosure research
Nuvation Bio Inc.
Data as of Jun 11, 2026. Collected disclosures, not exhaustive history.
30-day and 12-month windows end Oct 15, 2026 and use transaction dates, not disclosure dates. The data-as-of date above reflects the latest collected disclosure and may be older than the window end.
| Mashal RobertDirector | Open-market purchaseNon-derivative security10b5-1 plan not indicated | 25,000 | $4.73 | $118,250.00 | 225,000 | Jun 9, 2026 | Jun 11, 2026SEC filing |
| Wentworth KerryCHIEF REGULATORY OFFICER | Open-market saleNon-derivative security10b5-1 plan indicated | 36,750 | $5.01 | $184,279.20 | 53,000 | Apr 17, 2026 | Apr 21, 2026SEC filing |
| Liu DongfangCHIEF MEDICAL OFFICER | Open-market saleNon-derivative security10b5-1 plan indicated | 50,000 | $5.02 | $251,000.00 | 18,000 | Apr 17, 2026 | Apr 21, 2026SEC filing |
| Wentworth KerryCHIEF REGULATORY OFFICER | Open-market saleNon-derivative security10b5-1 plan indicated | 200,000 | $4.52 | $903,560.00 | 53,000 | Apr 6, 2026 | Apr 8, 2026SEC filing |
| FALBERG KATHRYN EDirector | Grant / awardDerivative security10b5-1 plan not indicated | 123,397 | — | — | 123,397 | May 21, 2026 | May 26, 2026SEC filing |
| BLICKENSTAFF KIM DDirector | Grant / awardDerivative security10b5-1 plan not indicated | 123,397 | — | — | 123,397 | May 21, 2026 | May 26, 2026SEC filing |
| VERNON W ANTHONYDirector | Grant / awardDerivative security10b5-1 plan not indicated | 123,397 | — | — | 123,397 | May 21, 2026 | May 26, 2026SEC filing |
| Cui XiangminDirector | Grant / awardDerivative security10b5-1 plan not indicated | 123,397 | — | — | 123,397 | May 21, 2026 | May 26, 2026SEC filing |
| Bazemore Robert BDirector | Grant / awardDerivative security10b5-1 plan not indicated | 123,397 | — | — | 123,397 | May 21, 2026 | May 26, 2026SEC filing |
| Mashal RobertDirector | Grant / awardDerivative security10b5-1 plan not indicated | 123,397 | — | — | 123,397 | May 21, 2026 | May 26, 2026SEC filing |
| Wentworth KerryCHIEF REGULATORY OFFICER | Option exerciseNon-derivative security10b5-1 plan indicated | 36,750 | $2.93 | $107,677.50 | 89,750 | Apr 17, 2026 | Apr 21, 2026SEC filing |
| Wentworth KerryCHIEF REGULATORY OFFICER | Option exerciseDerivative security10b5-1 plan indicated | 36,750 | — | — | 215,250 | Apr 17, 2026 | Apr 21, 2026SEC filing |
| Liu DongfangCHIEF MEDICAL OFFICER | Option exerciseNon-derivative security10b5-1 plan indicated | 50,000 | $1.94 | $97,000.00 | 68,000 | Apr 17, 2026 | Apr 21, 2026SEC filing |
| Liu DongfangCHIEF MEDICAL OFFICER | Option exerciseDerivative security10b5-1 plan indicated | 50,000 | — | — | 430,000 | Apr 17, 2026 | Apr 21, 2026SEC filing |
| Wentworth KerryCHIEF REGULATORY OFFICER | Option exerciseNon-derivative security10b5-1 plan indicated | 100,000 | $1.87 | $187,000.00 | 153,000 | Apr 6, 2026 | Apr 8, 2026SEC filing |
| Wentworth KerryCHIEF REGULATORY OFFICER | Option exerciseNon-derivative security10b5-1 plan indicated | 100,000 | $1.94 | $194,000.00 | 253,000 | Apr 6, 2026 | Apr 8, 2026SEC filing |
| Wentworth KerryCHIEF REGULATORY OFFICER | Option exerciseDerivative security10b5-1 plan indicated | 100,000 | — | — | 400,000 | Apr 6, 2026 | Apr 8, 2026SEC filing |
| Wentworth KerryCHIEF REGULATORY OFFICER | Option exerciseDerivative security10b5-1 plan indicated | 100,000 | — | — | 300,000 | Apr 6, 2026 | Apr 8, 2026SEC filing |
| Hung DavidPRESIDENT AND CEO, Director, 10% Owner | Grant / awardDerivative security10b5-1 plan not indicated | 1,995,012 | — | — | 1,995,012 | Feb 27, 2026 | Mar 3, 2026SEC filing |
| Wentworth KerryCHIEF REGULATORY OFFICER | Grant / awardDerivative security10b5-1 plan not indicated | 748,130 | — | — | 748,130 | Feb 27, 2026 | Mar 3, 2026SEC filing |
| Cui XiangminDirector | Grant / awardDerivative security10b5-1 plan not indicated | 74,813 | — | — | 74,813 | Feb 27, 2026 | Mar 3, 2026SEC filing |
| Hattersley GaryCHIEF SCIENTIFIC OFFICER | Grant / awardDerivative security10b5-1 plan not indicated | 748,130 | — | — | 748,130 | Feb 27, 2026 | Mar 3, 2026SEC filing |
| Markel StacyCHIEF PEOPLE OFFICER | Grant / awardDerivative security10b5-1 plan not indicated | 748,130 | — | — | 748,130 | Feb 27, 2026 | Mar 3, 2026SEC filing |
| Hanley David C.CHIEF TECHNICAL OPERATIONS | Grant / awardDerivative security10b5-1 plan not indicated | 748,130 | — | — | 748,130 | Feb 27, 2026 | Mar 3, 2026SEC filing |
| Liu DongfangCHIEF MEDICAL OFFICER | Grant / awardDerivative security10b5-1 plan not indicated | 748,130 | — | — | 748,130 | Feb 27, 2026 | Mar 3, 2026SEC filing |
| Makunje MosesSEE REMARKS | Grant / awardNon-derivative security10b5-1 plan not indicated | 50,761 | — | — | 68,137 | Feb 27, 2026 | Mar 3, 2026SEC filing |
| Makunje MosesSEE REMARKS | Grant / awardDerivative security10b5-1 plan not indicated | 224,439 | — | — | 224,439 | Feb 27, 2026 | Mar 3, 2026SEC filing |
| Sjogren ColleenChief Commercial Officer | Grant / awardDerivative security10b5-1 plan not indicated | 748,130 | — | — | 748,130 | Feb 27, 2026 | Mar 3, 2026SEC filing |
| Sauvage PhilippeChief Financial Officer | Grant / awardDerivative security10b5-1 plan not indicated | 748,130 | — | — | 748,130 | Feb 27, 2026 | Mar 3, 2026SEC filing |
Review the entire collected insider disclosure history with a free account.
Full collected history is available here after sign-in, separate from the public 12-month window. It is not an exhaustive trading history.
The largest open-market transaction by reported value in the public window was an open-market sale by Wentworth Kerry on Apr 6, 2026: $903,560.00, involving 200,000 shares. Reported price: $4.52.
11 public-window transactions explicitly indicate a 10b5-1 plan. A missing indication is not proof that a transaction was discretionary. Prices and values are shown only when reported; unavailable fields are not filled with zero.
Collected disclosures show 0 open-market purchases and 0 sales with transaction dates in the trailing 30 days ending Oct 15, 2026. Net reported purchase less sale value is $0.00. The latest collected disclosure data is as of Jun 11, 2026. These counts do not represent every insider action.
0 distinct insiders appear in collected disclosures for transaction dates in the trailing 30 days ending Oct 15, 2026. The latest collected Form 4 was filed on Jun 11, 2026. A filing date is not the transaction date.
This page shows 29 collected transactions dated in the trailing 12 months ending Oct 15, 2026. 0 older collected transactions are summarized outside this window and can be viewed here after sign-in. This is collected disclosure coverage, not exhaustive history; 10b5-1 plan status and derivative securities are labeled per record.
Insider data covers the trailing 12 months on public tables. Congressional tables cover all saved disclosures. Neither is an exhaustive history. Form 4 filing dates and congressional disclosure dates may differ from trade dates. Congressional amounts are ranges, not estimated dollar totals. Disclosure activity alone does not establish intent or predict returns.
From disclosure to research
Create a workspace for filing analysis and research notes. Filing-alert availability depends on your plan. Review the plan features separately; opening the plans page does not create an alert.